Product guide · Restricted substance
Holy Grail Ephedrix 60 caps
Stimulant formula from Holy Grail, 60 capsules. This guide sets out what the manufacturer states about the composition of Holy Grail Ephedrix 60 caps, what independent research says about its main ingredients, and the safety and regulatory points that apply. It contains substances that are not authorised as food or medicine in the EU. This guide is educational: it does not recommend use and gives no directions for use.
Back to the product- Named ingredients
- 6
- Amounts stated
- 2 of 6
- Status
- Restricted substance
- Evidence summaries
- 5
Overview
Manufacturer informationIngredients & composition
Manufacturer information| Ingredient | Amount |
|---|---|
| Ephedra extract | 50 mg |
| DMAA (1,3-dimethylamylamine) | Not stated |
| Caffeine | 150 mg |
| Synephrine HCl | Not stated |
| ProGBB | Not stated |
| Alpha-yohimbine | Not stated |
The manufacturer does not state the amount of 4 of the 6 ingredients. Without amounts, the research summarised in this guide cannot be related to this product's dose.
Not covered in detail in this guide: ProGBB.
Scientific background
Independent researchEphedra and ephedrine
Ephedra (Ephedra sinica, ma huang) contains ephedrine alkaloids, which stimulate the sympathetic nervous system. Ephedrine is also a licensed medicine in some indications2.
DMAA (1,3-dimethylamylamine)
DMAA (1,3-dimethylamylamine, methylhexanamine) is a synthetic stimulant that constricts blood vessels and raises blood pressure. It has been sold in pre-workout and weight-loss supplements and as a recreational stimulant3.
Caffeine
Caffeine is a stimulant that blocks adenosine receptors in the brain, reducing perceived effort and fatigue. It is found in coffee, tea and energy drinks and is a common ingredient in pre-workout products4.
Dicaffeine malate (sold as Infinergy®) is caffeine bonded to malic acid. Its caffeine adds to the total caffeine in a product, but labels do not always state the caffeine equivalent.
Synephrine (bitter orange, Citrus aurantium)
p-Synephrine is the main protoalkaloid of bitter orange (Citrus aurantium). It is structurally related to adrenaline and is used in weight-loss and pre-workout products5.
Yohimbine (yohimbe bark, rauwolscine)
Yohimbine is an alkaloid from the bark of the African tree Pausinystalia yohimbe. It blocks α2-adrenergic receptors, which increases noradrenaline release. Rauwolscine (alpha-yohimbine) is a closely related alkaloid.
Research evidence
Independent researchEphedra and ephedrine
A meta-analysis of clinical trials found that ephedra or ephedrine produced modest short-term weight loss of about 0.9 kg a month more than placebo, with no data on long-term weight loss and insufficient evidence for athletic performance2.
DMAA (1,3-dimethylamylamine)
No controlled trials show that DMAA improves athletic performance or weight loss. A pharmacokinetic study of a single 25 mg dose did not find meaningful changes in resting heart rate, blood pressure or body temperature6.
Caffeine
The International Society of Sports Nutrition concludes that caffeine consistently improves exercise performance when consumed in doses of about 3–6 mg per kg of body mass, with benefits for muscular endurance, movement velocity, strength, sprinting, jumping and aerobic exercise4.
Synephrine (bitter orange, Citrus aurantium)
A review of human clinical studies reported small increases in energy expenditure and modest weight loss with bitter orange extract or p-synephrine products over 6–12 weeks, many in combination with other ingredients5.
Yohimbine (yohimbe bark, rauwolscine)
A small trial in professional soccer players found reduced body fat with yohimbine but no change in body mass, muscle mass or performance7. Larger, independent trials are lacking.
Evidence limitations
Independent researchThis product does not state all ingredient amounts, so the doses used in research cannot be compared with what one serving provides.
The studies summarised in this guide examined single ingredients. No published study has tested this product or this combination of ingredients.
Ephedra and ephedrine
The trials were short and did not assess long-term outcomes2.
DMAA (1,3-dimethylamylamine)
The single-dose study does not reflect repeated use, higher doses or combination with other stimulants and exercise6. Analyses of sports and weight-loss supplements have repeatedly found stimulants that were not declared, or quantities different from the label89.
Caffeine
Responses vary widely between people, partly because of genetics and habitual caffeine use. Many studies use pure caffeine, so results do not automatically apply to multi-ingredient products4.
Synephrine (bitter orange, Citrus aurantium)
Most studies are small, short and use multi-ingredient products, and longer studies are needed to establish efficacy and safety5.
Yohimbine (yohimbe bark, rauwolscine)
Evidence for fat loss or performance is limited to small studies. Supplement labels are often inaccurate: of 49 US yohimbine supplements tested, only 2 gave accurate information on both the quantity and the known adverse effects10.
Safety & potential risks
For this product
The manufacturer states 150 mg of caffeine (as stated). EFSA considers single doses of up to 200 mg, and up to 400 mg a day from all sources, safe for healthy adults1, so count other sources taken the same day.
- Do not exceed 2 capsules per day.
- Consult with a healthcare professional before use.
Ephedra and ephedrine
Use of ephedra or ephedrine with caffeine was associated with an increased risk of psychiatric, autonomic and gastrointestinal symptoms and heart palpitations2.
DMAA (1,3-dimethylamylamine)
DMAA is a potent pressor agent. Cases of cerebral haemorrhage have been reported in adults after using DMAA3.
Caffeine
EFSA concluded that single doses of up to 200 mg, and daily intakes of up to 400 mg from all sources, do not raise safety concerns for healthy adults. For pregnant and breastfeeding women, daily intakes up to 200 mg do not raise concerns for the foetus or infant1.
Higher intakes can cause anxiety, sleep disturbance, raised heart rate and blood pressure, and digestive upset. Combining several caffeine sources (coffee, energy drinks, pre-workouts) raises total intake14.
Synephrine (bitter orange, Citrus aurantium)
The reviewed studies did not report serious adverse effects at the doses tested5, but combining synephrine with caffeine and other stimulants increases cardiovascular stress. People with high blood pressure, heart-rhythm disorders or taking stimulant or antidepressant medication should avoid it.
Yohimbine (yohimbe bark, rauwolscine)
A review of poison-centre cases found that adverse events with yohimbine products had more serious outcomes than average exposures, including rapid heart rate, anxiety, high blood pressure and agitation11. People with heart conditions, high blood pressure, anxiety disorders or taking antidepressants should not use yohimbine.
Regulatory status
Contains Ephedra extract. Ephedra species and their preparations are prohibited in foods, including food supplements, in the EU (Regulation (EC) No 1925/2006, Annex III, Part A). Contains 1,3-dimethylamylamine (DMAA), a synthetic stimulant that is not authorised as a novel food in the EU and is on the WADA Prohibited List.
Ephedra and ephedrine
Ephedra species and their preparations are prohibited in foods, including food supplements, in the EU (Regulation (EC) No 1925/2006, Annex III, Part A)12. Ephedrine is prohibited in competition by the World Anti-Doping Agency above a urinary threshold13.
DMAA (1,3-dimethylamylamine)
DMAA is not authorised as food or as a food supplement ingredient in the EU14 and is prohibited in competition by the World Anti-Doping Agency813.
Caffeine
Caffeine is permitted in EU foods and food supplements, subject to labelling rules. It is not on the World Anti-Doping Agency Prohibited List13.
Synephrine (bitter orange, Citrus aurantium)
Bitter orange extracts are used in EU food supplements under national rules, which differ between Member States15.
Scientific references
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the safety of caffeine. EFSA Journal. 2015;13(5):4102. DOI 10.2903/j.efsa.2015.4102
- Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537-1545. PubMed 12672771
- Gee P, Tallon C, Long N, et al. Use of recreational drug 1,3-dimethylamylamine (DMAA) associated with cerebral hemorrhage. Ann Emerg Med. 2012;60:431-434. PubMed 22575212
- Guest NS, VanDusseldorp TA, Nelson MT, et al. International Society of Sports Nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr. 2021;18:1. PubMed 33388079
- Stohs SJ, Preuss HG, Shara M. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int J Med Sci. 2012;9:527-538. PubMed 22991491
- Schilling BK, Hammond KG, Bloomer RJ, et al. Physiological and pharmacokinetic effects of oral 1,3-dimethylamylamine administration in men. BMC Pharmacol Toxicol. 2013;14:52. PubMed 24090077
- Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. 2006;14:289-299. PubMed 17214405
- Cohen PA, Travis JC, Keizers PHJ, et al. Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol (Phila). 2018;56:421-426. PubMed 29115866
- Cohen PA, Travis JC, Vanhee C, et al. Nine prohibited stimulants found in sports and weight loss supplements. Clin Toxicol (Phila). 2021;59:975-981. PubMed 33755516
- Cohen PA, Wang YH, Maller G, et al. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Test Anal. 2016;8:357-369. PubMed 26391406
- Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother. 2010;44:1022-1029. PubMed 20442348
- Regulation (EC) No 1925/2006 on the addition of vitamins and minerals and of certain other substances to foods. Official Journal of the European Union. Source
- World Anti-Doping Agency. The Prohibited List (current edition). Source
- Regulation (EU) 2015/2283 on novel foods. Official Journal of the European Union. Source
- Directive 2002/46/EC on the approximation of the laws of the Member States relating to food supplements. Official Journal of the European Union. Source
- Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union. Source
Sources checked against PubMed, Crossref or the official publisher on 2026-11-04. Manufacturer information is taken from the product's own data and has not been independently tested.

The product
Holy Grail Ephedrix 60 caps
€49,90